Immune responses to a recombinant, four-component, meningococcal serogroup B vaccine (4CMenB) in adolescents: A phase III, randomized, multicentre, lot-to-lot consistency study
- 1 September 2015
- Vol. 33 (39) , 5217-5224
Abstract
No abstract availableKeywords
Funding Information
- Novartis Vaccines
This publication has 30 references indexed in Scilit:
- The Disease Burden of Invasive Meningococcal Serogroup B Disease in CanadaThe Pediatric Infectious Disease Journal, 2013
- The changing and dynamic epidemiology of meningococcal diseaseVaccine, 2012
- Epidemiology of meningococcal disease in Latin America: current situation and opportunities for preventionNeurological Research, 2010
- The concept of ?tailor-made?, protein-based, outer membrane vesicle vaccines against meningococcal diseaseVaccine, 2005
- MeNZB?: a safe and highly immunogenic tailor-made vaccine against the New Zealand serogroup B disease epidemic strainVaccine, 2005
- Vaccine Potential of theNeisseria meningitidis2086 LipoproteinInfection and Immunity, 2004
- Identification of Vaccine Candidates Against Serogroup B Meningococcus by Whole-Genome SequencingScience, 2000
- Effect of outer membrane vesicle vaccine against group B meningococcal disease in NorwayThe Lancet, 1991
- ANTIGENIC SIMILARITIES BETWEEN BRAIN COMPONENTS AND BACTERIA CAUSING MENINGITISThe Lancet, 1983
- Immunologic Response of Man to Group B Meningococcal Polysaccharide VaccinesThe Journal of Infectious Diseases, 1972